| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PC5-VC-PAB-MMAE targets the microtubule network within cells through its payload, MMAE (monomethyl auristatin E). MMAE is a potent antimitotic agent that binds to tubulin, a key protein in the formation of microtubules. By inhibiting tubulin polymerization, MMAE disrupts microtubule dynamics, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis. The targeting is achieved through the antibody component of the ADC, which specifically binds to an antigen overexpressed on the surface of cancer cells. PC5-VC-PAB-MMAE itself is a linker-payload conjugate that, when attached to an antibody, enables the selective delivery of MMAE to the target cells.
|
|---|---|
| ln Vitro |
In vitro, PC5-VC-PAB-MMAE demonstrates significant biological activity by disrupting microtubule dynamics, thereby inhibiting cell proliferation. As a component of an ADC, its activity is dependent on the antibody's ability to bind to its target antigen and internalize the conjugate into the cell. Once inside the target cell, the linker is cleaved (typically in the lysosome), releasing the potent tubulin inhibitor MMAE. The released MMAE then binds to tubulin and inhibits microtubule polymerization, leading to cell cycle arrest and apoptosis. This mechanism of action makes PC5-VC-PAB-MMAE a highly effective payload for targeted cancer therapy.
|
| ln Vivo |
In vivo, PC5-VC-PAB-MMAE is not administered as a free drug; it is conjugated to an antibody to form an ADC. As an ADC, it is designed to deliver the toxic payload specifically to tumor cells, thereby reducing systemic toxicity and improving the therapeutic index. The in vivo activity of an ADC containing PC5-VC-PAB-MMAE would be characterized by its ability to selectively inhibit tumor growth in animal models expressing the target antigen. However, specific in vivo data for this linker-payload conjugate alone are not available.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assay protocols are not directly applicable to PC5-VC-PAB-MMAE, as it is a linker-payload conjugate. Its activity is assessed in cell-based assays to measure its antiproliferative effects after conjugation to an antibody. The linker's stability and cleavage characteristics can be evaluated in vitro using plasma stability assays or lysosomal enzyme assays to ensure the payload is released in the target cell.
|
| Cell Assay |
In vitro cell-based assay protocols for PC5-VC-PAB-MMAE typically involve its evaluation as part of an ADC. The ADC is incubated with target antigen-positive cancer cells, and its ability to inhibit cell proliferation is measured using standard assays like MTT or CellTiter-Glo. The potency is often expressed as an IC50 value. Control experiments with antigen-negative cells are used to confirm target specificity. The mechanism of action can be confirmed by assessing cell cycle arrest at G2/M phase and induction of apoptosis.
|
| Animal Protocol |
In vivo animal experimental protocols are not applicable to PC5-VC-PAB-MMAE as a standalone compound. The conjugate is designed for use in ADCs, and its in vivo efficacy is evaluated in xenograft models using the fully assembled ADC. The ADC is administered intravenously, and tumor growth inhibition is monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to PC5-VC-PAB-MMAE as a standalone compound. When conjugated to an antibody, the ADC's pharmacokinetics are primarily determined by the antibody. The linker-payload conjugate itself is not intended for administration.
|
| References | |
| Additional Infomation |
PC5-VC-PAB-MMAE is a research-grade linker-payload conjugate used in the development of antibody-drug conjugates (ADCs). It is not a drug itself and has not entered clinical trials. Its mechanism of action involves the targeted delivery of the potent tubulin inhibitor MMAE to cancer cells via an antibody, leading to cell death. The compound is available exclusively for research purposes.
|
| Exact Mass |
1402.721
|
|---|---|
| CAS # |
2922216-98-4
|
| PubChem CID |
171706640
|
| Appearance |
White to off-white solid powder
|
| Density |
1.243±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
|
| Boiling Point |
1341.3±65.0 °C(predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
99
|
| Complexity |
2610
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCC(=O)OC4=C(C(=C(C(=C4F)F)F)F)F
|
| InChi Key |
ZZSMZLNVMAIJOK-OTAUHYOLSA-N
|
| InChi Code |
InChI=1S/C69H99F5N10O15/c1-15-39(8)59(47(96-13)34-49(86)84-33-21-25-46(84)61(97-14)40(9)63(89)77-41(10)60(88)43-22-17-16-18-23-43)82(11)67(93)57(37(4)5)81-66(92)58(38(6)7)83(12)69(95)98-35-42-28-30-44(31-29-42)78-64(90)45(24-20-32-76-68(75)94)79-65(91)56(36(2)3)80-48(85)26-19-27-50(87)99-62-54(73)52(71)51(70)53(72)55(62)74/h16-18,22-23,28-31,36-41,45-47,56-61,88H,15,19-21,24-27,32-35H2,1-14H3,(H,77,89)(H,78,90)(H,79,91)(H,80,85)(H,81,92)(H3,75,76,94)/t39-,40+,41+,45-,46-,47+,56-,57-,58-,59-,60+,61+/m0/s1
|
| Chemical Name |
(2,3,4,5,6-pentafluorophenyl) 5-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~200 mg/mL (~142.49 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
